Cancer News: Breast
Breast cancer patients were able to conceive after treatment using embryo cryopreservation after ovarian stimulation, according to a new study.
Breast cancer patients treated with a one-week partial breast irradiation saw no increase in cancer recurrence or difference in cosmetic outcomes compared to women who received standard treatment.
Several sleep attributes, such as sleep duration and snoring, may affect survival on breast cancer patients, a new study suggests.
Women with endocrine-resistant metastatic breast cancer managed to keep cancer away longer when treated with the novel drug, palbociclib, a new study shows.
Female breast cancer survivors were able to lose weight through modest lifestyle changes tackling obesity, a major risk factor for breast cancer, a new study reveals.
A newer form of a less invasive mastectomy technique was found to be safe and equally beneficial for breast cancer patients compared to more invasive techniques.
Breast cancer patients who follow an exercise program during chemotherapy experience less fatigue, nausea and pain - and need fewer adjustments to their dosage.
A review of 700 BRCA-positive breast cancer cases showed that removing ovaries significantly reduces the risk of death, especially for BRCA1 (62% lower).
According to the latest guidelines, women with inflammatory breast cancer (a rare type of breast cancer) should be offered less invasive surgery if appropriate.
Palbociclib, which has been approved by the US FDA for advanced breast cancer, was shown to help patients who have already received treatment for their condition.
Researchers detailed the surprising ways in which breast cancer builds resistance to the drug lapatinib, and how to prevent it.
A new phase 2 study shows that the preoperative combination of gemcitabine, carboplatin, and iniparib is well tolerated in breast cancer patients.
The majority of all breast cancers can be diagnosed using magnetic resonance imaging (MRI), researchers report.
Women with breast cancer who receive goserelin had higher pregnancy rates 2 years after treatment, a study shows.
Having first-degree relatives with a history of prostate cancer increases a woman’s risk of developing breast cancer, according to a new study.
Breast cancer survivors found to be prone to thyroid cancer, especially within five years of their breast cancer diagnosis according to a new comparative analysis.
Women with breast cancer may avoid surgical removal of the breast if they undergo chemotherapy before a cancer operation.
A trial showed that an investigational medication for breast cancer improved progression free survival in patients with Hormone-Resistant positive (HR+) tumors.
The FDA approved Palbociclib for the treatment of postmenopausal women with advanced breast cancer that is hormone receptor-positive.
Ultrasound was found to be an effective tool in determining which breast cancer patients really need to proceed with surgical removal of lymph nodes.
Some older women with breast cancer may avoid radiotherapy, without harming their chances of survival, a study has shown.
Increased overall survival in women with breast cancer who received Eribulin, a chemotherapeutic agent, as a first and second line chemotherapy regimen.
Almost all women with HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug were cancer-free after 3 years.
A gene, identified to be overactive in triple-negative breast cancer, raises hopes for new targeted treatments in this aggressive difficult-to-treat cancer subtype.
Researchers found that providing nutrition education to breast cancer patients may help them prevent reoccurrence of the disease.
A new study on experimental drug, Palbociclib, gives hope to women with advanced breast cancer as it doubled progression-free survival in patients.
Herceptin, when combined with chemotherapy, improves significantly long-term survival of patients with HER-2 positive breast cancer.
Adding Carboplatin or bevacizumab to standard chemotherapy treatment increased the proportion of breast cancer with no residual cancer detected at surgery.
Breast cancer patients who retained ovarian function after chemotherapy benefited by ovarian suppression, either with tamoxifen or with aromatase inhibitor.
Women with metastatic breast cancer benefited from a treatment combining eribulin and capecitabine in a clinical trial, as presented in the latest conference.